Skip to main content

Innovative Nanoformulation of Antimicrobial Peptides to Treat Bacterial Infectious Diseases

Objective

Resistance to traditional antibiotics is a rapidly increasing problem that in a few years could make infections impossible to treat and bring the state of medical care back to the pre-antibiotic era from the beginning of the last century. Antimicrobial peptides (AMPs) have a huge potential as new therapeutics against infectious diseases as they are less prone to induce resistance due to their fast and non-specific mechanism of action. The aim of FORMAMP is to explore a number of innovative formulation and delivery strategies based on nanotechnology in order to improve the efficiency and stability of AMPs in clinical development. Functional delivery systems that can be applied directly on the infected site will be developed for treatment of infections in skin and burn wounds, as well as lung infections caused by Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and Mycobacterium tuberculosis (MTB). Formulation and delivery strategies to prevent and treat biofilm formation related to these conditions will be developed. Different nanoformulation platforms, particularly promising for peptide delivery, controlled release strategies and technologies against proteolytic degradation of peptides will be evaluated in the project. These include lipid-based systems such as lipidic nanocapsules, polymer-based structures such as dendrimers and microgels as well as nanostructured mesoporous silica. The possibility to formulate the nanostructured materials into efficient drug delivery systems such as a topical spray or gel and pulmonary aerosol will be evaluated. The effect of nanoformulated AMPs will be evaluated with state-of-the art in vitro models and in vivo models. The results of this interdisciplinary project will generate efficient treatment strategies combatting one of the largest threats to our health care system today, reducing healthcare costs and expand the growth of European enterprises within the field of pharmaceutics and nanomaterials.

Field of science

  • /medical and health sciences/health sciences/infectious disease
  • /engineering and technology/nanotechnology/nano-materials

Call for proposal

FP7-NMP-2013-LARGE-7
See other projects for this call

Funding Scheme

CP-IP - Large-scale integrating project

Coordinator

RISE RESEARCH INSTITUTES OF SWEDEN AB
Address
Brinellgatan 4
501 15 Boras
Sweden
Activity type
Research Organisations
EU contribution
€ 1 523 012,20
Administrative Contact
Lovisa Ringstad (Dr.)

Participants (15)

MAX IV Laboratory, Lund University
Sweden
EU contribution
€ 675 040
Address
Paradisgatan 5C
22100 Lund
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Artur Schmidtchen (Prof.)
UPPSALA UNIVERSITET
Sweden
EU contribution
€ 583 440
Address
Von Kraemers Alle 4
751 05 Uppsala
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Eva Nises Ahlgren (Mrs.)
UNIVERSITAET ULM
Germany
EU contribution
€ 515 600
Address
Helmholtzstrasse 16
89081 Ulm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Michaela Schuhmacher (Mrs.)
ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands
EU contribution
€ 530 868
Address
Hanzeplein 1
9713 GZ Groningen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Peter Braun (Dr.)
Pergamum AB
Sweden
EU contribution
€ 250 800
Address
Kisp Fogdevreten 2
171 65 Solna
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ulrika Wennberg (Ms.)
LAKEMEDELSVERKET
Sweden
EU contribution
€ 180 373
Address
Dag Hammarskjolds Vag 42
75103 Uppsala
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Ambjörn Lindqvist (Mr.)
SP PROCESS DEVELOPMENT AB
Sweden
EU contribution
€ 703 492
Address
Po Box 857
501 15 Boras
Activity type
Research Organisations
Administrative Contact
Bo Lassen (Dr.)
POLYMER FACTORY SWEDEN AB
Sweden
EU contribution
€ 353 552
Address
Teknikringen 48 1 Tr
114 28 Stockholm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Andreas Nyström (Dr.)
UNIVERSITE D'ANGERS
France
EU contribution
€ 528 480
Address
Rue De Rennes 40
49035 Angers Cedex 01
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Patrick Saulnier (Prof.)
CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS
France
EU contribution
€ 199 680
Address
Rue Larrey 4
49100 Angers
Activity type
Other
Administrative Contact
Amina Moussa (Mrs.)
KUNGLIGA TEKNISKA HOEGSKOLAN
Sweden
EU contribution
€ 662 040
Address
Brinellvagen 8
100 44 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Barbara Karan (Ms.)
INHALATION SCIENCES SWEDEN AB
Sweden
EU contribution
€ 510 637,80
Address
Halsovagen 7
141 57 Huddinge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Fredrik Sjövall (Mr.)
XSPRAY PHARMA AB (PUBL)
Sweden
EU contribution
€ 367 240
Address
Gunnar Asplunds Alle 32
171 63 Solna
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Magnus Andersson (Dr.)
ADENIUM BIOTECH APS
Denmark
EU contribution
€ 232 810
Address
Ole Maaloesvej 3
2200 Kobenhavn
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Peter Nordkild (Dr.)
POLYPEPTIDE LABORATORIES (SWEDEN) AB
Sweden
EU contribution
€ 128 429
Address
Box 30089
200 61 Limhamn
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Lars Andersson (Dr.)